Purpose: Breakthrough cancer pain (BTcP) lacks for standards for diagnosis, assessment and management. This study is aimed at reaching consensus on the application of criteria to diagnosis and on the appropriate use of rapid-onset fentanyl formulations (ROOs).
Methods: A Spanish group of medical oncology experts was invited to participate in a consensus process thorough a modified 2-round internet-based Delphi survey. Panellists were asked to rate agreement with each statement using a 9-point Likert scale, and median consensus scores (MED) and interquartile ranges (IQR) were calculated to measure expert consensus after both rounds: agreement on a statement was defined as a MED score ≥7 (consensus with the statement) and an IQR <3 (agreement
Methods: A Spanish group of medical oncology experts was invited to participate in a consensus process thorough a modified 2-round internet-based Delphi survey. Panellists were asked to rate agreement with each statement using a 9-point Likert scale, and median consensus scores (MED) and interquartile ranges (IQR) were calculated to measure expert consensus after both rounds: agreement on a statement was defined as a MED score ≥7 (consensus with the statement) and an IQR <3 (agreement